STOCK TITAN
  1. Home
  2. News
  3. QURE

uniQure N.V. - QURE STOCK NEWS

Welcome to our dedicated news page for uniQure N.V. (Ticker: QURE), a resource for investors and traders seeking the latest updates and insights on uniQure N.V..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect uniQure N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of uniQure N.V.'s position in the market.

News
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
Rhea-AI Summary
uniQure N.V. (QURE) reported promising clinical updates for AMT-130 in Huntington’s disease, FDA clearance for IND applications, strategic reorganization for cost savings, and a strong cash position. Financially, the company holds approximately $618 million in cash as of December 31, 2023, with revenues of $15.8 million for 2023. However, there was a significant net loss of $308.5 million in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
earnings
-
News
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
Rhea-AI Summary
uniQure N.V. (NASDAQ: QURE) announced updated interim data from Phase I/II clinical trials of AMT-130 for Huntington’s disease, showing preserved neurological function and favorable trends in neuronal degradation with generally well-tolerated gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.79%
Tags
clinical trial
-
News
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
Rhea-AI Summary
CSL (ASX: CSL; USOTC: CSLLY) announced the three-year results from the pivotal HOPE-B study confirming continued long-term durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb) gene therapy for hemophilia B. The treatment offers elevated and sustained factor IX activity levels for years, reducing the rate of annual bleeds and the need for regular prophylactic infusions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
News
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
uniQure N.V. (NASDAQ: QURE) granted 142,300 restricted share units and options to purchase 52,500 ordinary shares to 28 newly hired employees as inducement to commence their employment. Each option has an exercise price of $7.30 per share, with a ten-year term and vesting over four years. The restricted share units vest in three annual installments beginning on December 7, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
none
-
News
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
Rhea-AI Summary
uniQure N.V. (NASDAQ: QURE) has received FDA clearance for its gene therapy candidate, AMT-191, for the treatment of Fabry disease. The company's chief medical officer, Walid Abi-Saab, M.D., highlighted the potential of AMT-191 as a one-time treatment incorporating proprietary technology. Patient enrollment for the Phase I/II trial is expected to begin in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
clinical trial
-
News
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Rhea-AI Summary
uniQure N.V. reported FDA clearance of Investigational New Drug (IND) application for AMT-260 in refractory mesial temporal lobe epilepsy and strategic reorganization to focus on advancing multiple clinical-stage programs, expecting $180 million of cost savings over the next three years. They have a strong cash position of approximately $660 million as of September 30, 2023, which is expected to fund operations into the second quarter of 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.68%
Tags
earnings
News
CSL and uniQure Win 2023 Prix Galien USA Award
Rhea-AI Summary
Global biotechnology leader CSL and uniQure N.V. have won the 2023 Prix Galien USA Award for Best Product for Rare/Orphan Diseases for their gene therapy HEMGENIX®. HEMGENIX is the first and only FDA-approved gene therapy for adults with hemophilia B. It has also received conditional marketing authorization in the European Union and Canada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
-
News
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
Rhea-AI Summary
uniQure N.V. announces 12 data presentations at the European Society of Gene and Cell Therapy Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
-
News
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
Rhea-AI Summary
uniQure announces strategic reorganization to reduce operating expenses and focus on clinical-stage programs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.61%
Tags
none
News
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
uniQure N.V. grants inducement equity awards to newly hired employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.9%
Tags
none
Stock QURE logo
uniQure N.V.

Nasdaq:QURE

QURE Rankings

#3662 Ranked by Market Cap
#5129 Ranked by Stock Gains
N/A Ranked by Dividends

QURE Stock Data

228.67M
37.70M
9.88%
81.66%
5.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Netherlands
Amsterdam

About QURE

uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.